49 related articles for article (PubMed ID: 23558916)
21. Rituximab in the treatment of non-Hodgkin's lymphoma--a critical evaluation of randomized controlled trials.
Griffin MM; Morley N
Expert Opin Biol Ther; 2013 May; 13(5):803-11. PubMed ID: 23560506
[TBL] [Abstract][Full Text] [Related]
22. Rituximab by subcutaneous route.
Solal-Celigny P
Expert Rev Hematol; 2015 Apr; 8(2):147-53. PubMed ID: 25749209
[TBL] [Abstract][Full Text] [Related]
23. Rituximab (Rituxan/MabThera): the first decade (1993-2003).
Grillo-López AJ
Expert Rev Anticancer Ther; 2003 Dec; 3(6):767-79. PubMed ID: 14686699
[TBL] [Abstract][Full Text] [Related]
24. Maintenance therapy for low-grade lymphomas: has the time come?
Cartron G; Solal-Céligny P
Curr Opin Oncol; 2007 Sep; 19(5):425-32. PubMed ID: 17762565
[TBL] [Abstract][Full Text] [Related]
25. Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma.
Grillo-López AJ; White CA; Varns C; Shen D; Wei A; McClure A; Dallaire BK
Semin Oncol; 1999 Oct; 26(5 Suppl 14):66-73. PubMed ID: 10561020
[TBL] [Abstract][Full Text] [Related]
26. Optimizing the use of rituximab for treatment of B-cell non-Hodgkin's lymphoma: a benefit-risk update.
Kunkel L; Wong A; Maneatis T; Nickas J; Brown T; Grillo-López A; Benyunes M; Grobman B; Dillman RO
Semin Oncol; 2000 Dec; 27(6 Suppl 12):53-61. PubMed ID: 11226001
[TBL] [Abstract][Full Text] [Related]
27. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention.
Jazirehi AR; Bonavida B
Oncogene; 2005 Mar; 24(13):2121-43. PubMed ID: 15789036
[TBL] [Abstract][Full Text] [Related]
28. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
Marcus R; Hagenbeek A
Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
[TBL] [Abstract][Full Text] [Related]
29. Pharmaceutical follow-up for patients on rituximab therapy for non-Hodgkin lymphoma: what is the evidence?
Hegele V; Stoll P; Wüst D; Ehrenbrink G; Grazziotin LR; Caregnato JP; Lindenmeyer LP
Int J Clin Pharm; 2013 Aug; 35(4):513-9. PubMed ID: 23737385
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics of rituximab and its clinical use: thought for the best use?
Cartron G; Blasco H; Paintaud G; Watier H; Le Guellec C
Crit Rev Oncol Hematol; 2007 Apr; 62(1):43-52. PubMed ID: 17287129
[TBL] [Abstract][Full Text] [Related]
31. Non-Hodgkin's lymphoma in the elderly. Part 1: Overview and treatment of follicular lymphoma.
Morrison VA
Oncology (Williston Park); 2007 Aug; 21(9):1104-10. PubMed ID: 17910313
[TBL] [Abstract][Full Text] [Related]
32. B cell non-Hodgkin's lymphoma: rituximab safety experience.
Mohrbacher A
Arthritis Res Ther; 2005; 7 Suppl 3(Suppl 3):S19-25. PubMed ID: 15960818
[TBL] [Abstract][Full Text] [Related]
33. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
Robak T; Lech-Maranda E; Robak P
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1529-43. PubMed ID: 20942624
[TBL] [Abstract][Full Text] [Related]
34. Rituximab in lymphoma: a systematic review and consensus practice guideline from Cancer Care Ontario.
Cheung MC; Haynes AE; Meyer RM; Stevens A; Imrie KR;
Cancer Treat Rev; 2007 Apr; 33(2):161-76. PubMed ID: 17240533
[TBL] [Abstract][Full Text] [Related]
35. Phase I to III trials of anti-B cell therapy in non-Hodgkin's lymphoma.
Martin P; Furman RR; Coleman M; Leonard JP
Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5636s-5642s. PubMed ID: 17875800
[TBL] [Abstract][Full Text] [Related]
36. Safety of rituximab in the treatment of B cell malignancies: implications for rheumatoid arthritis.
Hainsworth JD
Arthritis Res Ther; 2003; 5 Suppl 4(Suppl 4):S12-6. PubMed ID: 15180892
[TBL] [Abstract][Full Text] [Related]
37. Monoclonal antibodies for the treatment of hematologic malignancies: clinical trials in Japan.
Tobinai K
Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S90-6. PubMed ID: 12819934
[TBL] [Abstract][Full Text] [Related]
38. Copanlisib: First Global Approval.
Markham A
Drugs; 2017 Dec; 77(18):2057-2062. PubMed ID: 29127587
[TBL] [Abstract][Full Text] [Related]
39. Application of the systematic review and bibliometric network analysis (SeBriNA) methodology contextualizes evidence. Part 2: rituximab for non-Hodgkin's lymphoma.
Kho ME; Brouwers MC
J Clin Epidemiol; 2012 Sep; 65(9):996-1009. PubMed ID: 22742915
[TBL] [Abstract][Full Text] [Related]
40. Safety of rapid rituximab infusion in adult cancer patients: a systematic review.
Lang DS; Hagger C; Pearson A
Int J Nurs Pract; 2011 Aug; 17(4):357-69. PubMed ID: 21781215
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
